Ratings Canopy Growth Corporation Nasdaq

Equities

CGC

CA1380357048

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-15 EDT			5-day change	1st Jan Change
9.91 ^USD	+2.16%		+9.75%	+93.93%

05-07	Investors wary of US cannabis ETFs despite recent rally	RE
05-07	Canopy USA Exercises Options to Acquire Wana, Jetty	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's enterprise value to sales, at 4.44 times its current sales, is high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CANOPY GROWTH CORPORATION	+93.93%	730M		-
DONG-E-E-JIAO CO.,LTD.	+45.15%	6.34B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-14.00%	4.61B		C+
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+9.54%	3.39B		C
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.99%	3.29B		B-
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.03%	2.02B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-6.97%	1.73B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.31%	1.67B	-	-
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+50.00%	1.63B		-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-10.61%	1.59B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes